body pharm semaglutide 6 🚨 Diabetes Guidelines Update 2026

Perhaps most telling is the comparison with GLP-1 receptor agonists as a class

Myofibroblast activation largely depends on a signaling network that hovers around the TGF- superfamily 41,79 , beginning with the release of TGF-1 from the TGF- latency associated peptide (LAP) in the ECM, prompted by multiple mechanisms, including mechanical stress sensing by the LAP-binding integrins V1 on myofibroblasts and v6 on activated epithelia 80,81 , binding to TGF- receptors 1 and 2, canonical SMAD signaling, translocation of SMAD2, SMAD3 and SMAD4 to the nucleus and promotion of the genes encoding SMA ( ACTA2 ) and ECM proteins

For Wegovy (weight management), the schedule starts at 0.25 mg weekly and increases monthly through 0.5 mg, 1 mg, 1.7 mg, and finally to the maintenance dose of 2.4 mg weekly

2017: The FDA approves Novo Nordisks Ozempic (semaglutide, a glucagon-like peptide-1 receptor agonist) to treat type 2 diabetes in eligible patients